- Home
- USGO vs COYA Comparison
USGO vs COYA Comparison
Compare USGO & COYA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- USGO
- COYA
- Stock Information
- Founded
- USGO 2015
- COYA 2020
- Country
- USGO United States
- COYA United States
- Employees
- USGO N/A
- COYA N/A
- Industry
- USGO Precious Metals
- COYA Biotechnology: Pharmaceutical Preparations
- Sector
- USGO Basic Materials
- COYA Health Care
- Exchange
- USGO Nasdaq
- COYA Nasdaq
- Market Cap
- USGO 117.3M
- COYA 99.8M
- IPO Year
- USGO 2023
- COYA 2022
- Fundamental
- Price
- USGO $8.25
- COYA $6.20
- Analyst Decision
- USGO Strong Buy
- COYA Strong Buy
- Analyst Count
- USGO 1
- COYA 3
- Target Price
- USGO $26.50
- COYA $16.67
- AVG Volume (30 Days)
- USGO 37.0K
- COYA 59.6K
- Earning Date
- USGO 08-12-2025
- COYA 08-11-2025
- Dividend Yield
- USGO N/A
- COYA N/A
- EPS Growth
- USGO N/A
- COYA N/A
- EPS
- USGO N/A
- COYA N/A
- Revenue
- USGO N/A
- COYA $3,685,107.00
- Revenue This Year
- USGO N/A
- COYA $106.97
- Revenue Next Year
- USGO N/A
- COYA N/A
- P/E Ratio
- USGO N/A
- COYA N/A
- Revenue Growth
- USGO N/A
- COYA N/A
- 52 Week Low
- USGO $5.00
- COYA $4.65
- 52 Week High
- USGO $14.46
- COYA $10.24
- Technical
- Relative Strength Index (RSI)
- USGO 39.64
- COYA 56.65
- Support Level
- USGO $8.09
- COYA $5.57
- Resistance Level
- USGO $8.78
- COYA $6.34
- Average True Range (ATR)
- USGO 0.43
- COYA 0.41
- MACD
- USGO -0.11
- COYA 0.04
- Stochastic Oscillator
- USGO 27.15
- COYA 63.46
About USGO U.S. GoldMining Inc. Common stock
US Goldmining Inc is a mineral exploration and development company. It is focused on the exploration and development of a project located in Alaska, USA. The company's sole property is Whistler Project which is a gold-copper exploration project located in the Yentna Mining District, approximately 170 km northwest of Anchorage, Alaska.
About COYA Coya Therapeutics Inc.
Coya Therapeutics Inc is a clinical-stage biotechnology company focused on developing proprietary medicinal products to modulate the function of regulatory T cells. It is developing its multi-modality Treg therapies for neurodegenerative, autoimmune, and metabolic diseases.